Kyung Dong Pharm
Introduction



KD KyungDong Pharm.

CONTENTS

Highlight	KD Highligt	04
Overview	About KD	06
	Corporate Identity	
	Enterprise Value	
	Organization Chart	
What we focus on	Manufacturing Sites	14
	R&D	
	Top 5 Sales Performance in 2024	

Kyung Dong Pharmaceutical,
devoted to promoting human health and happiness,is boldly advancing onto the global stage.

KD KyungDong Pharm.

Highlight

01

R&D Oriented Global Pharmaceutical Company


Since its founding in 1975, Kyung Dong Pharm has been dedicated to the development of specialized therapeutics and developed medicines using our own technologies, which depended on imports in the past. Since the 1990s, we have been actively pioneering overseas markets, and have contributed to the pharmaceutical industry and also enhanced the national prestige by exporting drug substances and drug products to 21 countries.

Export Tower Awards(5)

One Million, Three Million, Five Million, Ten Million, and Twenty Million Dollar Export Awards.

API (Active Pharmaceutical Ingredient) Export

Japan
Clopidogrel
Teneligliptin
Risperidone
Roxatidine
Istradefylline




FDF(Finished Dosage Formulation) Export

Myanmar
Gabapen Cap.
Megasphen Tab.

Cambodia
Aclova Tab.
Atenol Tab.

Vietnam
Iziton Tab.

Philippines
Ceftison Inj.
Uronal SR Tab.
Rebamide Tab.



Donations and Contributions


Over KRW 399 billion(USD 29 million) in cumulative donations (2002–2025)

02

A company that practices sharing and works together

Kyung Dong Pharm. currently manufactures over 90 pharmaceutical products, contributing to the public health and well-being. Committed to fulfilling its corporate social responsibilities, Kyung Dong actively donates its profits into society, promoting shared prosperity and fostering an inclusive, compassionate community.

Social Contribution



OVERVIEW

01 About KD

02 Corporate Identity

03 Enterprise Value

04 Organization Chart

Overview







About KD

Kyung Dong Pharm, which started as a specialized manufacturer of therapeutic drugs in 1975, has achieved enormous amounts of import substitution effects through the synthesis of new drugs and the development of new formulations, whichdependedonimportsinthepastthroughendlessresearchanddevelopment, and contributed to the pharmaceutical industry and improving national health by producing and supplying excellent drugs using entirely domestic technology.


Company Name	Kyung Dong Pharmaceutical Co., Ltd.
CEOs	Ryu Ki-Sung, Kim Kyung-Hoon
Established	September 9, 1975
Head Office	3F, Smart-K Building B, 26 Gwacheondaero 7-gil, Gwacheon-si, Gyeonggi-do, Korea
Annual Revenue	KRW 196.2 billion (approx.)

Overview

Corporation Identity

Logo Concept

Kyung Dong Pharmaceutical's new corporate identity (CI) is inspired by ginkgo leaf, a symbol of health and hope. The design reflects the company's core philosophy : "Contributing to the health and happiness of humanity." The ginkgo shapes symbol embodies this mission, while the use of a rounded box element conveys a sense of stability and balance, aligned with our core values of trust and care.





Color System

KD Deep Ivy		KD Crowberry Blue		KD Mint		KD Grey	
R 33	C 90	R 0	C 70	R 73	C 70	R 87	C 0
G 107	M 50	G 54	M 0	G 169	M 10	G 87	M 0
B 94	Y 70	B 69	Y 0	B 147	Y 50	B 86	Y 0
# 216B5E	K 0	# 003645	K 85	# 49A993	K 0	# 575756	K 80

50th Anniversary Emblem

Kyung Dong Pharmaceutical's 50ths anniversary emblem, inspired by the concept of "Infinite KD", embodies the company's boundless drive for growth and its enduring spirit of innovation. The emblem visually symbolizes Kyung Dong's remarkable 50 year journey and limitless potential, combining the KD signature color with a refined design motif. It reflects our unwavering commitment to becoming a century lasting company, dedicated to health and happiness of humanity.



Color System

 # 005766

R 0	C 100
G 87	M 56
B 102	Y 52
	K 15

 # 00a070

R 0	C 90
G 160	M 0
B 112	Y 70
	K 0

Corporate Value

Belief Driven Leadership in Social Responsibility

At Kyung Dong, we uphold the leadership grounded in a strong belief in social responsibility. Every employees of our company is encourage to internalize and embody these corporate values, ensuring that all employees contribute to driving the company forward. These values serve not only as a collective promise, but as a guiding principle that defines the direction Kyung Dong strive toward together.

21st century paradigm

01

Mission :

Respect for Life and Improvement of Value of Life

It is the mission of Kyung Dong, the purpose of our existence and our future objective. It is the greatest orientation of our executives and staff members who not only produce outstanding products but also respect all lives and further put importance on and emphasize improving the value of human life while thinking of the mission all the time and uniting the employees.

02

Vision :

Sharing Management Aiming to Guide Health and Happiness

It is an emphasis on the future dreamed by Kyung Dong Pharm, that is, the future to be realized. The future begins with the present. Kyung Dong Pharm's vision is inextricably linked with the mission of respect for life. Instead of focusing solely on creating profit-making, which is the clear purpose of a company, we have decided not to neglect the fair distribution of profits and returning them to society. Our objective is management that practice sharing outside the company through innovation management that takes place inside the company.

03


Core value :

Sincerity and Diligence, Creation and Development, Heartful Service

These are the core values of Kyung Dong Pharm that Chairman Ryu Deok-Hee enacted celebrating its 10th anniversary in 1985. This is a code of conduct for the company that exists to realize the mission and vision of Kyung Dong Pharm. By providing values that can be shared, sympathized, and practiced by all stakeholders of Kyung Dong Pharm, we have provided guidelines for families of Kyung Dong Pharm to act according to our mission and vision. This continues to date and is rooted in the unique corporate culture of Kyung Dong Pharm.

Organization Charts

Kyung Dong Pharmaceutical's organizational structure consists of the General Meeting of Shareholders, Board of Directors, Auditor, CEO, Executive Division, Management Division, R&D Center, Business Division, and Manufacturing Division. We are committed to transparent and fair management, continuously pursuing improvements to maintain an efficient and effective organizational framework.



What we focus on

01 Manufacturing Sites

02 R&D

03 Top 5 Sales Performance in 2024

What we focus on

Manufacturing Sites

Kyung Dong began operating its GMP certified facilities in 1987, manufacturing diverse product portfolio through formulation development, active ingredient synthesis and new drug development. In 2012, the implementation of RFID based logistic system to prevent shipping errors and enable first-in, first-out inventory management. This established a reliable foundation for exporting both API and FDF to the global market. Kyung Dong currently operates pharmaceutical manufacturing sites in Yanggam and Baran, located in Hwaseong, Korea. Each site is strictly managed for quality and produces incrementally modified drugs, combination drugs and cephalosporin class antibiotics.



01	Oral Solids	• Tablets • Capsules
02	Active Pharmaceutical Ingredient	• Sterile & Lyophilized API synthesis • General API synthesis
03	Injections	• Injection (ampoule) • Lyophilized injection
04	Cephalosporin	• Drug products (tablets, capsules, powder injections) • Active Pharmaceutical Ingredient (sterile & lyophilized synthesis)



What we focus on

Manufacturing Site

Yanggam Site

The Yanggam site is comprised of four main facilities: solid dosage, sterile, cephalosporin, and smart logistics center. The solid dosage facility is equipped with both tablet and capsule production lines. The sterile facility is equipped for ampoules and lyophlilzed injectables. The Yanggam site also features a dedicated cephalosporin facility, capable of manufacturing lyohililzed APIs, as well as finished dosage formulations, including tablets, capsules and powder for injection.

01

Solid Dosage



02

Sterile



03

Cephalosporin



04

Smart logistics



What we focus on



Main Manufacturing Equipment in Solid Dosage Facility

Equipment Name	Quantity
Mixer	2
Granulator	3
Drying machine	2
Oscillator	4
Roller compactor	2
Tablet press	6

Equipment Name	Quantity
Capsule filling machine and checkweigher	2
Coating machine	4
Automatic sorting machine	2
Counter (bottle packaging) line	3
Blister packing machine line	3

Major Equipment in Solid Dosage Facility

❶ Large capacity granulation line
Granulator (GMA600) / Drying machine (BFS240) / Oscillator (BTS200)

❷ Automatic sorting machine (TVIS NS)

❸ Tablet press (KORSCH XL200)

❹ Mixer (Bin blender, PM600, GEA)



01 Yanggam Site

Solid Dosage Facility

The solid dosage facility was completed in 2006 in full compliance with EU-GMP standards and received KGMP certification. At the time of construction, state-of-the-art equipment from BOHLE, KORSCH, and BOSCH (Germany) was installed via a turn-key system. An IBC (Intermediate Bulk Container) system was adopted to implement a closed manufacturing environment, minimizing external exposure during production. The facility has an annual capacity of over 600 million units, and in 2024, it introduced advanced equipment capable of precise granulation control. The site is now fully equipped for high-quality multilayer tablet production, aligning with the highest global standards in solid dosage manufacturing.

Floor Information for Solid Dosage Facility

1F	Production line (tablets, capsules)
	Packaging line (bottles, PTP blisters)
2F	Manufacturing support equipment (Air conditioning, manufacturing water, purified water, compressed air)
	Storage (materials)
	Quality lab









What we focus on

02 Yanggam Site

Sterile Facility

The sterile facility was completed in 2008 and has since been approved under both KGMP and BGMP standards for the production of sterile pharmaceutical products, including ampoules, lyophilized injectables, and sterile APIs. To ensure optimal sterile conditions, the facility is equipped with a VAV (Variable Air Volume) and automated environmental control system, which automatically adjusts inter-room pressure differentials and includes an alarm based monitoring function. In 2016, the facility received PMDA (Japan) approval, further validating its capability to manufacture high-quality sterile APIs for international markets.



Floor Information for Sterile Facility

1F	Production line (tablets, capsules), Process control and quality laboratory
	Storage (ingredients, primary materials, refrigerated ingredients)
	Manufacturing support equipment (air conditioning, compressed air, pure steam generator (PSG))
2F	Production line (injection_ampoule)

Sterile Packaging Building

Packaging line (ampoules, freeze-dried vials), Storage (secondary materials)
Manufacturing support equipment (purified water and injection water manufacturing equipment)



Major Equipment in Sterile Facility

❶ Moist heat sterilizer / Dry heat sterilizer

❷ Preparation tank





Major Manufacturing Equipment in Sterile Facility

Equipment Name	Quantity
Dry heat sterilizer	3
Moist heat sterilizer	2
Ampoule filling line (on-line) (Washer + sterilizing tunnel + filling machine)	1

Equipment Name	Quantity
Automatic liquid filling machine	1
Lyophilizer	2
Automatic inspection machine	2

03 Yanggam Site

Cephalosporin Facility

The cephalosporin facility was remodeled in 2009 to expand its sterile processing area and add additional powder filling lines. In 2015, an automated powder filling system was introduced to enhance production efficiency. Through continuous expansion of manufacturing equipment and ongoing improvements to production lines and processes, Kyung Dong Pharm has strengthened its high-quality manufacturing system for antibiotic formulations.



Floor Information for Cephalosporin Facility

1F	Production line (tablets, capsules), in-process control & quality control laboratory, packaging line (non-sterile)
	Storage (ingredients, primary materials, refrigerated ingredients)
2F	Production line (sterile synthesis_lyophilization, powder injections)
	Manufacturing support equipment (air conditioning, compressed air, pure steam generator (PSG), packaging line (sterile), storage (finished dosages))
3F	Manufacturing support equipment (Purified water and water for injection manufacturing equipment)

Major Manufacturing Equipment in Cephalosporin Facility

Equipment Name	Quantity
Granulator/drying machine /mixer	1 each
Tablet press	1
Coating machine/ Sorting machine	2
Capsule filling machine	1
Counter (bottle packaging)	1
Blister packing machine	1

API Lyophilization & Powder Injection Manufacturing Equipment

Equipment Name	Quantity
Dry heat/ moist heat sterilizer	1 each
Lyophilizer	1
Powder vial filling line (on-line) (Washer + sterilizing tunnel + filling machine + sealing machine)	1
External vial washer	1
Vial labeling machine	1
Vial cartoner	1



Major Manufacturing Equipment in Cephalosporin Facility

❶ Drying machine

❷ Capsule filling machine





What we focus on

04 Yanggam Site

Smart Logistics Center

Completed in 2014, the smart logistics center participated in the government's pilot project for RFID system implementation, successfully establishing a serial number tracking system for ETC (ethical drugs).In the first half of 2020, RFID tracking was extended to health functional foods, further enhancing traceability and inventory accuracy. The facility also adopted a Digital Picking System (DPS) to improve operational efficiency in the outbound process, streamlining picking accuracy and reducing shipment lead times.





Major Equipment in Smart Logistics Center

❶ Wireless forklift

❷ RFID wireless recognitionlogistics system

❸ Storage (raw materials, refrigerated materials)



Manufacturing Site

Baran Site Base

The Baran site consists of two main facilities: the administration building and the production facility. Completed in 2014 in compliance with cGMP standards and certified by KGMP in 2015, the site is currently focused on the production of active pharmaceutical ingredients (APIs). With an annual capacity of over 15 tons, the facility serves as a key hub for API manufacturing. In response to increasing export demands, Kyung Dong is planning the installation of new equipment to expand production output.

What we focus on



Major Manufacturing Equipment in Baran Production Facility

Equipment Name	Quantity
Reactor (SUS)	6
Reactor (Glass)	5
Filter	8
Double cone drying machine	1
Rotary drying machine	3

Equipment Name	Quantity
Filtration & Drying machine	1
Oscillator	2
Jet mill	1
Roller compactor	1
Pilot scale manufacturing set	1



01 Baran Site

Baran Production Facility





Major Manufacturing Equipment in Baran Production Facility

❶ GL 500

❷ GL 5000(A)


What we focus on

01 Research Field

Active Pharmaceutical Ingredients

Finished Dosage Formulation

Kyung Dong Pharm researches and develops APIs and FDFs focusing on chronic diseases such as diabetes and hypertension, which are increasing due to rapid aging and changes in living environment. The majority of Kyung Dong Pharm's items are specialized treatments prescribed in hospitals, and are laying its foundation through thorough quality control and safety management, and we are focusing on drug discovery to increase drug efficacy and improve side effects. Furthermore, we are building an expanded pipeline to challenge the various therapeutic markets, and focusing all our capabilities on expanding the domestic and foreign markets based on research technology accumulated over the past 50 years.




02 R&D Center

Synthesis Research Department

Formulation Research Department

The R&D Center in Hwaseong-si is largely composed of the Synthesis Research Department and the Pharmaceutical Research Department. The Synthesis Research Department is conducting various studies aiming at manufacturing high-purity, high-quality APIs through quality improvement on ingredients and process improvement. We have manufactured a large number of APIs by ourselves for the first time in Korea, and are constantly researching various analysis methods for quality improvement and process improvement to enhance the quality and stability of existing APIs. In addition, we are focusing on the development of new synthetic methods that can manufacture and produce high-purity, low-cost, high-value-APIs by establishing specialized strategies through various patent analysis. The Formulation Research Department is researching candidates for development with the goal of designing formulations that can efficiently deliver drugs and securing new formulation technologies that can compensate for the disadvantages of existing formulations. In addition, we strive to meet the unmet needs in the market by increasing the reliability of our products through increasing medicinal efficacy and improving side effects, and by forming a diversified portfolio of incrementally modified drugs and generic drugs.




03 R&D Investment

New product development

Expanding the drug pipeline

Strengthening R&D capability system

Kyung Dong Pharm has accumulated a lot of experience and know-how in pharmaceutical research technology and synthetic research technology, and continues to expand its investment to strengthen its R&D research capabilities. We are strengthening the foundation for future growth by developing differentiated new products, expanding new drug pipelines, and strengthening R&D capability systems.



04 Major Research Status

Incrementally Modified Drug

Overseas Business Development

Kyung Dong Pharm is dedicated to the development, manufacturing, and commercialization of finished pharmaceutical products and active pharmaceutical ingredients. Leveraging our expertise in pharmaceutical research and process development, we focus on developing differentiated value-added medicines and innovative API manufacturing technologies to strengthen our presence in both domestic and global markets.With continuous investment in research and development, we are expanding our new drug pipeline, advancing our R&D capabilities, and fostering innovation to build a solid foundation for sustainable future growth.

Project Name	Adapting	Discovery	Pre-Clinical	Clinical Phase I	Clinical Phase II	Clinical Phase III	Approval
KDF1905	Urology						
KD2408	Obesity, Diabetes						
KD2502	Dyslipidemia						
KD2503	Dry Eye Disease						
KD2406	Gastroenterology						
KD2504 KD2505	Diabetes						
KD2405	Nephrology						
KD2506	NSAID Combination						
KD2507	NSAID Combination						

Update. 2026. 05

05 R&D History

First in Korea :
In-House API Synthesis Method

First in Korea :
In-House New Drug Formulation

❶ Korea's First Substance Synthesis Development

Substance	Development Year	Contents
Difemerine HCl	1991	Antispasmodic, Limerine tablet / injection
Tiropramide HCl	1994	Antispasmodic, gastrointestinal motility modulating drug, Taron tablet / injection
Aceclofenac	1998	Analgesic and anti-inflammatory drug, Acer tablet / capsule
Rebamipide	2001	Gastritis and gastric ulcer treatment, Rebamide tablet
Famciclovir	2004	Antiviral agent, Famclovir tablet

❷ Korea's First Research on New Formulations

Classification	Development Year	Contents
Antihypertensive drug (Dilopine extended releasing tablet)	1998	Sustained release of poorly soluble substance
Benign prostatic hypertrophy treatment (Uronal sustained release tablet)	2004	Change the dosage form to improve the convenience of use (capsule → sustained release tablet)
Antipyretic analgesic (Gnal-N tablet, GnalN-Q triple tablet)	2009	Antipyretic analgesic film coated triple tablet
Antihypertensive combination drug (patented)	2009	Tablet and capsule containing granules

❶ Korea's First Substance Synthesis Development

Kyung Dong Pharm succeeded in developing the first synthetic method of tiropramide hydrochloride in Korea for 5 years from 1992. At the time, it was developed and supplied in Korea exclusively by the Italian company Rotta, and in the meantime, in Korea, all substances equivalent to KRW 10 billion were imported. In 1994, we succeeded in synthesizing and developing substances with our own technology. In 1998, we developed and marketed injectables and tablets, creating an alternative effect of substance imports of about KRW 2 billion per year at the time.

In addition, after a research and development period of 1 year and 8 months from 1996, we succeeded in developing and commercializing aceclofenac synthesis method for the first time in Korea. At the time, this substance was produced exclusively by Prones Parma in Spain, supplied to the whole world, and Korea was also dependent on imports. The Kyung Dong Pharm Research Center developed an innovative method for manufacturing aceclofenac with high yield (96%), completed patent application, and successfully completed manufacturization research to achieve commercialization, recording sales of over KRW 6 billion annually.

In 2001, Rebamide tablet, a rebamipide ingredient formulation, was developed as the first generic for Otsuka Pharmaceutical's Mukosta tablet, and Kyung Dong Pharm was the first to apply for the patent for new method of substance synthesis in Japan as well as various other countries. As a result, the patent was first registered in the United States in January 2004, which was even faster than in Korea.

In 2003, we developed the first anti-viral agent, Famciclovir, using the substance synthesis method the first time in Korea. And in 2004, we released Famclovir tablets, recording annual sales of approximately KRW 6 billion. Famclovir tablet has been consigned to several pharmaceutical companies in Korea to be produced, and was released with many records, including the longest research period and the highest number of litigation cases in the history of Kyung Dong Pharm. A total of 8 cases were filed, including 6 trials to verify the scope of rights, 1 trial to invalidate, and a patent infringement lawsuit filed by Novartis. We won all the cases until the judge ruled in favor of us in January 2007.

❷ Korea's First Research on New Formulations

Kyung Dong Pharm succeeded in developing several new formulations for the first time in Korea after years of research. We succeeded in formulations after several challenges regarding the research on formulation modification through sustained release preparation in matrix form, sustained release of poorly soluble drugs, and sustained release technology. Dilopine extended releasing tablet is a product mainly composed of the poorly soluble substance felodipine, and with characteristics that are difficult to formulate because of its small dose and sustained release. The key to research and development was to contain small amounts of water-insoluble formulations, and to maintain a constant blood level when taking them so that a sustained-release effect is produced. Kyung Dong Pharm succeeded in formulating sustained-release tablets by dissolving felodipine and high polymers in an organic solvent and matrixing them, after researching on maintaining the matrix form without using a solubilizing agent. Since then, based on the research power that developed Dilopine extended releasing tablets, in 2004, we developed the extended releasing formulation technology for Tamsurosin, our first generic, and acquired a patent. The original developer's formulation was a capsule, but Kyung Dong Pharm developed a unique product by succeeding in the study of changing the formulation to a sustained release preparation that is easier to take than a capsule.

06 Creation of Intellectual Property Rights through innovative R&D

Innovative Research & Development

Patent Applications

The source of growth for the pharmaceutical industry is research on new products and new technologies, and Kyung Dong Pharm is investing heavily in R&D to realize the value. We developed new intermediates and salts and excellent yield synthetic routes through research on drug substances, and items that can realize the maximum effect, minimum side effects, and economic efficiency through research on formulation changes and sustained release according to pharmaceutical properties to create strong intellectual property rights. As of April 2026, we hold 62 domestic and international patents, reflecting our ongoing commitment to research and development and the expansion of our intellectual property portfolio.

❶ Active Pharmaceutical Ingredient

Product	Number of Patent	Registered Country
Roxatidine	1	KOR
Saxagliptin	3	KOR, JPN
Itraconazole	1	KOR
Isepamicin	2	KOR
Clopidogrel Camsylate	1	KOR
Cisapride	2	KOR
Tofacitinib	1	KOR
Varenicline	1	KOR

❷ Finished Dosage Formulation

Classification	Product	Number of Patent	Registered Country
Antiviral drug	Famclovir tablet	12	KOR, USA, JPN, CHN, AUS, EUR
Urinary system agent	Uronal SR tablet	6	KOR, USA, JPN, CHN, AUS, EUR
	Solfecin tablet	4	KOR, USA, JPN, AUS
Circulatory system agent	Losazol tablet	3	KOR, JPN
	Inhipla tablet	3	KOR
Peptic ulcer agent	Rebamid tablet	4	KOR, USA, JPN, EUR
	Zanitin tablet/capsule	3	KOR
Antihypertensive	Dilopin ER tablet	1	KOR
	Valtrep tablet	1	KOR
Gastrointestinal motility modulating drug	Levopren tablet	1	KOR
Quinolone	Lefoxin tablet	5	KOR
Antihistamine	Starizin tablet	1	KOR
Analgesic	Ketolan injection	1	KOR
	Celeca tablet	2	KOR, JPN

❸ Others

Classification	Product	Number of Patent	Registered Country
Bio substance	Peptide	1	KOR
	Lipase and producing microorganisms	1	KOR
Composition / Formulation	Piroxicam External preparation	1	KOR

❹ Number of Patents Pending

Classification	Product	Number of Patent	Registered Country
Drug Substances	Tenofovir	1	KOR

What we focus on

07 Research Performance-Export Status


Global Market Research

Export Market Analysis

Kyung Dong Pharm launched a full-scale overseas market research since 1993 and has collected a wide variety of information on items that can be exported, regional export conditions, pharmaceutical companies, pharmaceutical systems, and future prospects, and has concluded or negotiated drug export contracts with various countries. In the process of deciding imports and exports, specific and accurate market analysis and sales plans are shared, and contracts are established at the optimal level where mutual interests are reasonably satisfied. Kyung Dong Pharm values principles and integrity, and builds trust by dealing with many companies in various countries.

API (Active Pharmaceutical Ingredient) Export

Japan
Clopidogrel
Teneligliptin
Risperidone
Roxatidine
Istradefylline




FDF(Finished Dosage Formulation) Export

Myanmar
Gabapen Cap.
Megasphen Tab.

Cambodia
Aclova Tab.
Atenol Tab.

Vietnam
Iziton Tab.

Philippines
Ceftison Inj.
Uronal SR Tab.
Rebamide Tab.



2025 Best Items in KD Sales Performance

01



Antihypercholesterolemic Drug

Duoroban Tab.

10/5mg · 10/10mg · 10/20mg

Ezetimibe
Rosuvastatin calcium

02



Combination Antihypertensive Drug

Valdipine Tab.

5/80mg · 5/160mg · 10/160mg

Amlodipine
Valsartan

03



Antihyperlipidemic Drug

Atrovan Tab.

10mg · 20mg

Atorvastatin

04



Combination Antihypertensive Drug

Valtrep Tab.

80mg · 160mg · Plus · Plus F

Valsaratan
Hydrochlorthiazide

05



Cerebrovascular Disease Treatment

Alfotin Soft tab.

Choline Alfoscerate 400mg

Items are selected based on the sales of the previous year, 2024, and may differ from the sales in 2025.

KD KyungDong Pharm.